AstraZeneca at ASCP 2026

Nov 17–20, 2026 Montréal, Canada ~1.5k attendees Website

AstraZeneca takes part in 3 sessions at ASCP 2026 in Montréal, and exhibits at Booth 208. Its program covers biomarker testing for cancer: reading and scoring HER2 staining in metastatic breast cancer, HER2 testing in other solid tumors and PTEN testing in metastatic prostate cancer.

OrganizationASCP 2026 Attendance
AstraZeneca
Cambridge, UK
◆Diamond Sponsor
Pharmaceutical and biotech companiesDiamond Sponsor
Global pharmaceutical company whose oncology medicines rely on biomarker tests such as HER2 and PTEN read by pathologists.
Booth
Exhibiting at Booth 208
Wed, Nov 1810am–4pmThu, Nov 199–11am · 12:15–3pm
Talk
Wed Nov 18
12–1pm
Talk
Fri Nov 20
12–1pm
PTEN in Metastatic Prostate Cancer
519A
Genitourinary pathology · Molecular pathology

Explore the full ASCP 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Montréal. Leave your work email and we’ll be in touch.

Privacy

Download the full ASCP 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at AstraZeneca

Tell us what you sell and we’ll find the people at AstraZeneca most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by the American Society for Clinical Pathology (ASCP) or the Canadian Association of Pathologists (CAP-ACP). Organization details are derived from the meeting’s published program, faculty list, poster list and exhibitor list, and each organization’s own website. Submit a correction